CA2143126A1 - Methode de preparation de plasma pauvre en facteur x - Google Patents

Methode de preparation de plasma pauvre en facteur x

Info

Publication number
CA2143126A1
CA2143126A1 CA 2143126 CA2143126A CA2143126A1 CA 2143126 A1 CA2143126 A1 CA 2143126A1 CA 2143126 CA2143126 CA 2143126 CA 2143126 A CA2143126 A CA 2143126A CA 2143126 A1 CA2143126 A1 CA 2143126A1
Authority
CA
Canada
Prior art keywords
factor
plasma
antibody
buffer
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2143126
Other languages
English (en)
Inventor
Shamay Tang
Kimberlyn F. Card
Leslie Motley
Hing Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dade International Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2143126A1 publication Critical patent/CA2143126A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96444—Factor X (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procédé de préparation de plasma appauvri en facteur X. Selon le procédé, on met en contact du plasma normal et un immunoadsorbant auquel est fixé un anticorps monoclonal dirigé contre le facteur X. Le facteur X se lie à l'immunoadsorbant et l'on récupère le plasma appauvri en facteur X. L'immunoadsorbant doté de l'anticorps dirigé contre le facteur X peut être réutilisé. On a également prévu des anticorps monoclonaux dirigés contre le facteur X.
CA 2143126 1993-07-01 1994-06-28 Methode de preparation de plasma pauvre en facteur x Abandoned CA2143126A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8647693A 1993-07-01 1993-07-01
US08/086,476 1993-07-01

Publications (1)

Publication Number Publication Date
CA2143126A1 true CA2143126A1 (fr) 1995-01-12

Family

ID=22198806

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2143126 Abandoned CA2143126A1 (fr) 1993-07-01 1994-06-28 Methode de preparation de plasma pauvre en facteur x

Country Status (5)

Country Link
EP (1) EP0660937A1 (fr)
JP (1) JPH08510555A (fr)
AU (1) AU7214294A (fr)
CA (1) CA2143126A1 (fr)
WO (1) WO1995001571A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19634312A1 (de) 1996-08-24 1998-02-26 Behringwerke Ag Verfahren zur Herstellung von Faktor V-Mangelplasma und ein so erhaltenes Mangelplasma
DE19720853A1 (de) * 1997-05-17 1998-11-19 Dade Behring Marburg Gmbh Erhöhung der FVII Empfindlichkeit eines Thromboplastinreagenzes
WO2005035753A1 (fr) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite remplaçant une proteine fonctionnelle
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2009101B1 (fr) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Procede de modification d'anticorps pour purifier un anticorps bispecifique
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
SE1050124A1 (sv) 2010-02-08 2011-08-09 Linkoping Biocontrols Ab Stabil lösning
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2017110980A1 (fr) 2015-12-25 2017-06-29 中外製薬株式会社 Anticorps présentant une activité accrue et son procédé de modification
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
US20190185578A1 (en) 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
PL3509637T3 (pl) 2016-09-06 2025-03-10 Chugai Seiyaku Kabushiki Kaisha Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
JP7841846B2 (ja) 2017-11-15 2026-04-07 ノヴォ ノルディスク アー／エス Ｆｘ活性化を促進する第ｘ因子結合剤
WO2023111018A1 (fr) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Anticorps contre le facteur de coagulation x et leurs utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59218960A (ja) * 1983-05-27 1984-12-10 Naraken 第ｘ因子欠乏血漿

Also Published As

Publication number Publication date
JPH08510555A (ja) 1996-11-05
WO1995001571A1 (fr) 1995-01-12
EP0660937A1 (fr) 1995-07-05
AU7214294A (en) 1995-01-24

Similar Documents

Publication Publication Date Title
CA2143126A1 (fr) Methode de preparation de plasma pauvre en facteur x
Novotny et al. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma
CA2112702C (fr) Methodes d'analyses et compositions pour la detection de proteases seriques, en particulier la proteine c activee
EP2554673B1 (fr) Nouvel anticorps monoclonal et procédé pour le test immunologique du dimère d
EP0162078B1 (fr) Procede d'isolation d'une proteine d'un melange la contenant et un anticorps specifique de conformation
JPH02163085A (ja) ヒト・プロテインｃの分離方法
JPH03504332A (ja) プロテインｃに対するモノクローナル抗体
US7439025B2 (en) Antibodies binding a gamma carboxyglutamic acid displaying epitope
EP0159025A2 (fr) Anticorps monoclonal spécifique de l'alpha 2 plasmine humaine
US20080274477A1 (en) Forms of Factor Xiia
WO2007008966A1 (fr) Dosage elisa pour détecter des formes multimériques d'une protéine
Howard et al. A monoclonal-antibody-based radioimmunoassay for measurement of protein C in plasma.
Mannhalter Biochemical and functional properties of factor XI and prekallikrein
Malm et al. Inhibition of human vitamin‐K‐dependent protein‐S‐cofactor activity by a monoclonal antibody specific for a Ca2+‐dependent epitope
AU631192B2 (en) Monoclonal antibody against c-reactive protein
JP2755753B2 (ja) アンチトロンビン３の生物活性測定法および測定用試薬
RU2445365C1 (ru) Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
JPH05113442A (ja) 免疫比濁測定方法
JPH0260267B2 (fr)
HU201844B (en) Immun adsorptive-amidolytic method for detecting plasminogen activator precursor (pro-uppa) and plasminogen activator (upa) of the human urine

Legal Events

Date Code Title Description
FZDE Dead